Guo D - Search Results

1

Photocatalytic deuterocarboxylation of alkynes with oxalate.

Xu P, Jiang HQ, Xu H, Wang S, Jiang HX, Zhu SL, Yin L, Guo D, Zhu X. Xu P, et al. Among authors: guo d. Chem Sci. 2024 Jul 15;15(32):13041-13048. doi: 10.1039/d4sc03586k. eCollection 2024 Aug 14. Chem Sci. 2024. PMID: 39148785 Free PMC article.

2

Benzodiazepine Derivatives as Potent Vasopressin V₂ Receptor Antagonists for the Treatment of Autosomal Dominant Kidney Disease.

Cao X, Wang P, Yuan H, Zhang H, He Y, Fu K, Fang Q, Liu H, Su L, Yin L, Xu P, Xie Y, Xiong X, Wang J, Zhu X, Guo D. Cao X, et al. Among authors: guo d. J Med Chem. 2022 Jul 14;65(13):9295-9311. doi: 10.1021/acs.jmedchem.2c00567. Epub 2022 May 17. J Med Chem. 2022. PMID: 35579344

3

Defluorinative Alkylation of Trifluoromethylbenzimidazoles Enabled by Spin-Center Shift: A Synergistic Photocatalysis/Thiol Catalysis Process with CO₂^•.

Xu P, Wang XY, Wang Z, Zhao J, Cao XD, Xiong XC, Yuan YC, Zhu S, Guo D, Zhu X. Xu P, et al. Among authors: guo d. Org Lett. 2022 Jun 10;24(22):4075-4080. doi: 10.1021/acs.orglett.2c01533. Epub 2022 Jun 1. Org Lett. 2022. PMID: 35648621

4

PF-06409577 inhibits renal cyst progression by concurrently inhibiting the mTOR pathway and CFTR channel activity.

Su L, Yuan H, Zhang H, Wang R, Fu K, Yin L, Ren Y, Liu H, Fang Q, Wang J, Guo D. Su L, et al. Among authors: guo d. FEBS Open Bio. 2022 Oct;12(10):1761-1770. doi: 10.1002/2211-5463.13459. Epub 2022 Jul 4. FEBS Open Bio. 2022. PMID: 35748097 Free PMC article.

5

Asymmetric synthesis of P-stereogenic phosphindane oxides via kinetic resolution and their biological activity.

Yin L, Li J, Wu C, Zhang H, Zhao W, Fan Z, Liu M, Zhang S, Guo M, Dou X, Guo D. Yin L, et al. Among authors: guo d, guo m. Nat Commun. 2024 Mar 21;15(1):2548. doi: 10.1038/s41467-024-46892-7. Nat Commun. 2024. PMID: 38514631 Free PMC article.

6

Benzothiazole derivatives as histone deacetylase inhibitors for the treatment of autosomal dominant polycystic kidney disease.

Cao X, Fan Z, Xu L, Zhao W, Zhang H, Yang Y, Ren Y, Xiao Y, Zhou N, Yin L, Zhou X, Zhu X, Guo D. Cao X, et al. Among authors: guo d. Eur J Med Chem. 2024 May 5;271:116428. doi: 10.1016/j.ejmech.2024.116428. Epub 2024 Apr 18. Eur J Med Chem. 2024. PMID: 38653068

7

Structural basis of tolvaptan binding to the vasopressin V₂ receptor.

Liu HL, Zhong HY, Zhang YX, Xue HR, Zhang ZS, Fu KQ, Cao XD, Xiong XC, Guo D. Liu HL, et al. Among authors: guo d. Acta Pharmacol Sin. 2024 Nov;45(11):2441-2449. doi: 10.1038/s41401-024-01325-5. Epub 2024 Jun 20. Acta Pharmacol Sin. 2024. PMID: 38902502

8

Notch3 as a novel therapeutic target for the treatment of ADPKD by regulating cell proliferation and renal cyst development.

Su L, Chen T, Hu H, Xu Z, Luan X, Fu K, Ren Y, Sun D, Sun Y, Guo D. Su L, et al. Among authors: guo d. Biochem Pharmacol. 2024 Jun;224:116200. doi: 10.1016/j.bcp.2024.116200. Epub 2024 Apr 10. Biochem Pharmacol. 2024. PMID: 38604258

9

Long-Residence Time Peptide Antagonist for the Vasopressin V₂ Receptor to Treat Autosomal Dominant Polycystic Kidney Disease.

Xiong X, Wang N, Zhang Y, Zhao W, Pang N, Fu K, Zhou N, Zhou X, Guo D. Xiong X, et al. Among authors: guo d. J Med Chem. 2024 Apr 11;67(7):5935-5944. doi: 10.1021/acs.jmedchem.4c00217. Epub 2024 Mar 20. J Med Chem. 2024. PMID: 38509003

10

Design of a nanozyme-based magnetic nanoplatform to enhance photodynamic therapy and immunotherapy.

Bai C, Liu J, Bai L, Yao D, Li X, Zhang H, Guo D. Bai C, et al. Among authors: guo d. J Pharm Anal. 2024 Sep;14(9):100928. doi: 10.1016/j.jpha.2023.12.018. Epub 2023 Dec 28. J Pharm Anal. 2024. PMID: 39345942 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7,865 results

Search Page

Filters